SHIEF / Shield Therapeutics raises funds to accelerate commercial opportunity for Accrufer iron deficiency treatment in US market

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that chief financial officer Hans-Peter Rudolf is stepping down from his position to purs more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which has developed a best-in-class anaemia treatment, has been going through the growing pains assoc more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is raising up to $27.5 million of new funds to support its development of Accrufer, its iron deficiency more_horizontal

There is life in the cryptocurrency sector yet, so it may seem. At least for GSTechnologies Ltd (LSE:GST), the London-listed financial technology smal more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its Accrufer iron deficiency treatment saw 173% growth in prescriptions in the second quarter, or more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said it is ‘very' optimistic about the future as it gears up for a full US commercial push of its lea more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the developer of a breakthrough oral drug for iron deficiency, has announced the appointment of indu more_horizontal

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) saw its shares jump 13% following an encouraging trading update. The company's main product, Accrufer, more_horizontal